profit from every $100 of sales.
$0$100
BioCryst Pharmaceuticals
$7.61-0.91% today
+10.3% in 1 year
1-year low $6.241-year high $11.11
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay $7.42 for every $1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What BioCryst Pharmaceuticals sold, what it kept, and what it did with the cash.
Sales went from $271 million in 2022 to $875 million in 2025, with $264 million of profit last year.
SalesProfit
BioCryst Pharmaceuticals vs. similar companies
BioCryst Pharmaceuticals grows the fastest of these 5 and is the cheapest for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| BioCryst Pharmaceuticals | 7.4× · Cheap | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads BioCryst Pharmaceuticals's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 271 | 331 | 451 | 875 | |
| 264 | 327 | 438 | 856 | |
| -148 | -104 | -3 | 341 | |
| -144 | -116 | 13 | 348 | |
| -247 | -227 | -89 | 264 | |
| -1.33 | -1.18 | -0.43 | 1.21 | |
| 97.6% | 98.6% | 97.3% | 97.8% | |
| -54.8% | -31.3% | -0.6% | 39.0% | |
| -91.2% | -68.4% | -19.7% | 30.2% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 550 | 517 | 490 | 514 |
| Cash | 305 | 111 | 105 | 90 |
| Total debt | 741 | 825 | 809 | 439 |
| Total liabilities | 845 | 972 | 966 | 633 |
| -295 | -456 | -476 | -119 | |
| 186 | 192 | 207 | 219 | |
| -25.7% | -25.2% | 2.7% | 85.6% | |
| 83.9% | 49.7% | 18.7% | -221.4% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -162 | -95 | -52 | 347 | |
| 1 | 2 | 1 | 2 | |
| -163 | -97 | -53 | 345 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 45 | 56 | 65 | 85 |
Valuation
- 7.4×
- 28.1×
- –
- -3.9×
- 2.2×
- 5.7×
- 6.6×
- 17.6%
- 13.5%
- 0.0%
Profitability
- 97.8%
- 39.0%
- 30.2%
- -42.3%
- -122.0%
- -21.0%
- 123.6%
- -98.5%
- -141.6%
- 21.4%
Growth
- +47.8%
- –
- +716.1%
- –
- +4.0%
Financial health
- 1.0×
- -1.55
- 184.5%
- -5.1×
- 1.91
- 1.88
- 1.90
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 5%of 871
Top 6%of 563
Top 13%of 867
Top 3%of 986
What analysts expect
- Average price target
- $25.00
- Range
- $25.00 – $25.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 6, 2026 | -0.03 | 0.06 | −150.0% |
| Feb 26, 2026 | 1.12 | 0.07 | +1,500.0% |
| Nov 3, 2025 | 0.06 | 0.07 | −14.3% |
| Aug 4, 2025 | 0.15 | 0.03 | +400.0% |
| May 5, 2025 | 0.00 | -0.07 | +100.2% |
| Feb 24, 2025 | -0.13 | -0.07 | −85.7% |
| Nov 4, 2024 | -0.07 | -0.07 | +0.0% |
| Aug 5, 2024 | -0.06 | -0.19 | +68.4% |
News
BioCryst is profitable. Now it wants to buy more rare disease drugsCNBC · Aug 28, 2026The newest story we have is from Aug 28, 2026.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
7/7Passes 7 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
69Pass
Benjamin Graham
70Pass
Philip Fisher
78Pass
Peter Lynch
100Pass
Joel Greenblatt
61Pass
Charlie Munger
68Pass
Terry Smith
74Pass
Questions about BioCryst Pharmaceuticals
Is BioCryst Pharmaceuticals a good stock to buy?
A strong, very profitable business, and the price looks low. 7 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the BioCryst Pharmaceuticals AI analysis
What does BioCryst Pharmaceuticals do?
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. It is in Biotechnology.
Does BioCryst Pharmaceuticals pay a dividend?
No. BioCryst Pharmaceuticals does not pay a dividend at the moment.
Is BioCryst Pharmaceuticals stock halal?
Yes. BioCryst Pharmaceuticals passes our halal screen: its business is permitted and its debt is 22% of its market value, under the 30% limit. How we check
How has BioCryst Pharmaceuticals stock done over the past year?
Up 10.3% over the past twelve months, to $7.61. It traded between $6.24 and $11.11 and is 31.5% below its high.
Who are BioCryst Pharmaceuticals's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with BioCryst Pharmaceuticals's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.